Biopharma Business

Tag "ReActiv8"

Operating expenses rise at Mainstay Medical as new trial begins

Medical device firm Mainstay Medical said operating expenses rose by $3.9 million for 2016 to $16.8 million as Mainstay kicked off its ReActiv-8 B clinical trial and began commercialising the

Read Full Article

Upcoming Events

[eventlist]

The Magazine

New Subscriber

Subscribe Here



Advertisements